The Safety and Effectiveness of Megace in HIV-Infected Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002345
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : October 2, 2007
Information provided by:
Bristol-Myers Squibb

Brief Summary:
To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.

Condition or disease Intervention/treatment Phase
Anorexia Cachexia HIV Infections Drug: Megestrol acetate Phase 4

Detailed Description:
Patients are randomized to receive 1 of 2 doses of Megace oral suspension daily for 24 weeks; at 12 weeks, those receiving the lower dose who have not gained 5 pounds over baseline or had appetite improvement to good or excellent are escalated to the higher dose. Patients are evaluated at 4-week intervals. Dose may be adjusted to maintain a desired weight.

Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patient must have:

  • HIV infection.
  • Evidence of HIV wasting syndrome that includes anorexia (appetite fair or poor) and weight loss >= 10 percent of pre-illness body weight.
  • Perception of weight loss as a detriment.
  • Life expectancy of at least 24 weeks.

Prior Medication:


  • Megestrol acetate for weight gain at a dose < 400 mg for < 60 days, provided therapy was discontinued at least 3 months prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Poorly controlled hypertension.
  • Heart failure.
  • Deep vein thrombosis.
  • Uncontrolled severe diarrhea.
  • Treatable active current infection (excluding chronic low-grade opportunistic infections).
  • Unable to intake food.
  • Impaired digestive/absorptive function.

Concurrent Medication:


  • Initiation during the study of any therapy to treat HIV or anorexia/cachexia (other than study drug).

Patients with the following prior conditions are excluded:

  • Hospitalization for or exacerbation of illness associated with weight loss within the past 2 weeks.
  • Participation in other investigational drug studies within the past month.
  • Previous abnormal mammogram (if 35-40 years of age) or abnormal mammogram within the past year (if over 40 years of age).

Prior Medication:


  • New antiviral therapy within the past 8 weeks.
  • Medications to promote weight gain (e.g., corticosteroid, dronabinol) within the past 2 months.
  • Megestrol acetate within the past 3 months. IV drug abuse not treated for at least 4 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002345

United States, California
Univ of California - Davis Med Ctr / CARES
Sacramento, California, United States, 95817
United States, Connecticut
Yale Univ Med School
New Haven, Connecticut, United States, 065102483
United States, District of Columbia
Georgetown Univ Med Ctr
Washington, District of Columbia, United States, 200072197
United States, Rhode Island
Miriam Hosp
Providence, Rhode Island, United States, 02906
Sponsors and Collaborators
Bristol-Myers Squibb

Additional Information: Identifier: NCT00002345     History of Changes
Other Study ID Numbers: 025C
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: October 2, 2007
Last Verified: October 2007

Keywords provided by Bristol-Myers Squibb:
Acquired Immunodeficiency Syndrome

Additional relevant MeSH terms:
HIV Infections
Wasting Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Weight Loss
Body Weight Changes
Body Weight
Metabolic Diseases
Nutrition Disorders
Megestrol Acetate
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents